Purpose: Irreversible electroporation has attractive attributes for focal ablation, namely nonthermal effect, precise demarcation of treatment and tissue selectivity. We report a prospective development study investigating focal irreversible electroporation. Materials and Methods: A total of 20 men with certain characteristics were recruited for study, including a visible index lesion on anterior magnetic resonance imaging that was concordant with transperineal targeted and template prostate mapping biopsy, absent clinically significant disease noted elsewhere (University College London definition 2) and prostate specific antigen 15 ng/ml or less. Our primary objective was to determine the side effect profile at 12 months. Secondary objectives included the domain specific toxicity profile using patient reported outcomes and early disease control using magnetic resonance imaging targeted biopsy. Results: A total of 19 patients with median age of 60 years (IQR 53e66) and median prostate specific antigen 7.75 ng/ml (IQR 5.5e10.03) were treated. Of the patients 16 were available for estimating the first outcome as 1 was lost to followup and 2 had received another form of treatment by study end. All 16 men had pad-free/leak-free continence at 12 months. The proportion of men with erection sufficient for penetration decreased from 12 of 16 (75%) to 11 of 16 (69%). No serious adverse events were recorded. There was a statistically significant improvement in urinary symptoms according to changes in UCLA-EPIC (UCLA Expanded Prostate Cancer Index Composite) and I-PSS (International Prostate Symptom Score) (p ¼ 0.039 and 0.001, respectively). Erectile function remained Accepted for publication September 9, 2016. No direct or indirect commercial incentive associated with publishing this article. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
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FACT-P ¼
FOCAL therapy has been proposed as an alternative strategy to maintain the oncologic benefit of radical treatments while decreasing treatment related side effects. 1 This strategy aims to treat the index lesion. It seems a legitimate option in light of new evidence showing that, although prostate cancer is generally multifocal, secondary low grade lesions have a slow and often indolent behavior. 2, 3 The proposition is that in the majority of cases the natural history of the disease seems to be driven by 1 aggressive clone located in the index lesion. 3, 4 Various sources of energy have been used to ablate prostate cancer in a focal manner. Across all series, pad-free continence, potency and absent residual disease were achieved in 95% to 100%, 54% to 100% and 83% to 100% men, respectively. 5 The majority of focal therapy series show the results of thermal sources of energy with a lethal effect that is a consequence of extreme temperatures. Cryotherapy needles decrease the temperature below À40C and HIFU devices raise the temperature above 60C. 6 Novel sources of energy might overcome the shortcoming of thermal technologies, which do not have well controlled and sharp demarcations between treated and untreated areas.
IRE seems to provide selective ablation with sharply demarcated margins in the target area. 7 Using pulsed, low energy direct current, IRE leads to cell apoptosis by the formation of nanopores within the membrane cell. 8 Further, ablation seems to be tissue selective with collagenous structures recovering after treatment, although this was recently challenged by a stage I study. 9, 10 IRE has to date been adopted at a few expert centers.
10e13 To our knowledge this is the first ethics committee approved, prospectively registered study evaluating focal IRE with intent to treat.
MATERIALS AND METHODS
Study Design
We have previously reported the design of NEAT (Nanoknife Electroporation Ablation Trial).
14 Briefly, this is a stage IIa, prospective development study adherent to the IDEAL recommendations for evaluating novel surgical procedures (ClinicalTrials.gov NCT01726894). 15 The trial was regularly audited by an independent data monitoring committee. Enrollment began in October 2013 and ceased in June 2014 with followup until September 2015. Men with visible anterior prostate cancer were invited to participate.
We decided to only treat anterior disease because to our knowledge the predictability of the IRE created ablative effect was hitherto unknown and staying anterior permitted plenty of prostate tissue to remain posterior to minimize the risk of rectal damage. The supplementary Appendix (http://jurology.com/) lists complete inclusion and exclusion criteria.
Study Interventions
Cancer Localization. Only men who underwent mpMRI and TPM were considered for this trial. mpMRI was done following a standardized protocol, including T2-weighted, diffusion-weighted and contrast enhanced sequences. 16 mpMRI was reported by an experienced radiologist with 10 years of experience with prostate imaging using the 27 sectors standardized scheme to draw the exact location of all lesions detected with a Likert score of 3 or greater.
Cancer localization was verified by TPM with 5 mm sampling density or by TPM with limited sampling plus targeted biopsy to mpMRI visible lesions. To be eligible the anterior MRI visible lesion had to be concordant with biopsy results. The presence of secondary lesions was permitted, provided that they were considered clinically insignificant according to UCL definition 2 (maximum cancer core length 3 mm or less and Gleason score 3 þ 3). 17 Irreversible Electroporation. Before the procedure, the MRI studies were uploaded in UCL SmartTargetÒ nonrigid image fusion software to facilitate planning. Focal IRE was performed with the patient under general anesthesia and in the lithotomy position. Antibiotics were administered at induction and deep muscle paralysis was achieved during the delivery of energy.
After having positioned a urethral or a suprapubic catheter, 19 gauge electroneedles were positioned transperineally under TRUS guidance through a brachytherapy grid. We used a biplanar Preirus TRUS probe (Hitachi Aloka Medical America, Wallingford, Connecticut) mounted on an EX 3Ô modular stepper fixed on the patient table. The needles were positioned at the margin of the target lesion with at least a 5 mm distance from the urethra. We used the NanoKnifeÒ system to deliver IRE.
The stepper was connected to an external platform to achieve TRUS image registration with the MRI. Based on an add-on algorithm to UCL SmartTarget, the software determined the location of the electroneedles on the brachytherapy grid. The operator was free to modify these coordinates based on judgment and discrepancies were recorded. The active length of each electroneedle can vary between 0.5 and 2 cm, which was determined by the operator based on the tumor craniocaudal extension. After inserting the needles, the distance between them was calculated on the axial TRUS view and uploaded in the device software ( fig. 1) .
The IRE protocol used included 90 pulses with a pulse length of 70 microseconds. Based on the needle distance from each other, the device developed a specific treatment planning. After achieving deep muscle paralysis, the first 10 pulses were delivered and the actual electrical field was measured. If this was within the target of 20 to 40 A, the remaining 80 pulses were delivered. Otherwise, treatment planning was modified accordingly before continuing tissue ablation. At the end of energy delivery the needles were pulled out and the catheter was left in place.
Focal IRE was performed as an outpatient procedure with discharge home the same evening or the following morning if the case was treated in the evening.
According to IDEAL guidelines in this early stage of assessment, we included a therapy escalation. Since we could not alter the treatment planning to deliver more energy (greater than 40 A may lead to thermal effects while less than 20 A may lead to under treatment), we decided to include a therapeutic escalation based on target volume in the first 9 patients. In the first group of 3 patients the upper threshold for treatment was a tumor volume representing 15% of prostate volume. This was increased at 40% and 50% for the second and third groups of 3 patients, respectively. Early toxicity data on each group of 3 men underwent mandatory independent data monitoring committee review prior to further treatments.
Followup. Early contrast MRI and catheter withdrawal were organized 3 to 10 days after ablation. Clinical review with PSA measurements was organized at 6 weeks, and 3, 6, 9 and 12 months. Patients responded to validated questionnaires at each time point and adverse events were recorded and scored using CTCAE, version 4 (see Appendix). The questionnaires included I-PSS, I-PSS QoL, IIEF-15, UCLA-EPIC, EQ-5DÔ QoL, FACT-P and MAX-PC.
At 6 months mpMRI was performed and reported with the likelihood of residual disease in the treated and untreated zones. All men underwent transperineal targeted biopsy of the treated area with at least 1 biopsy per 1 ml residual tissue. Additional targeted biopsies were performed in case of Likert 3 or greater disease found elsewhere. As in the selection process, UCL definition 2 was used to define residual clinically significant disease after focal IRE ablation.
Objectives
The primary objective was to determine the side effect profile of focal IRE. Secondary objectives included determining the domain specific toxicity profile, early disease control and the rate of trifecta (erection sufficient for intercourse, leak-free continence and absent clinically significant disease).
Statistical Analysis
In light of the primary outcome, sample size was calculated around common genitourinary side effects after prostate cancer treatment. With an expected 5% rate of incontinence and a 10% rate of erectile dysfunction, we estimated that 20 patients would represent an optimal sample size to determine precise estimates around these key outcomes.
14 Continuous variables are given as the median and IQR, and categorical variables are shown as the frequency and percent. Variation in continuous variables between visits is shown using box and whisker plots. To determine whether there were significant differences in continuous variables between the baseline and 12-month visits, the 2-tailed Wilcoxon signed rank test was used. Statistical significance was considered at p 0.05 and data were analyzed with SPSSÒ, version 20.0.
RESULTS
Study Population
Of the 20 patients who were recruited 19 were treated while 1 was excluded because of Of the 19 patients 16 completed all trial visits and the 12-month followup. One of the remaining 3 patients elected to continue followup elsewhere from 12 months and thereafter, and 2 men with residual disease underwent focal HIFU and radical prostatectomy at 10 and 11 months, respectively. As the primary outcomes were calculated as the variation between baseline and the 12-month visit, these 3 patients were censored from this analysis. They were still considered in the estimation of adverse events, histological outcomes and variation of patient reported outcome measures all throughout the study.
In terms of men with pad-free and pad-free/leakfree continence, the proportion remained stable between baseline and 12-month followup at 16 of 16 (100%, 95% CI 81e100). In terms of absolute erectile function, the proportion of men with erection sufficient for penetration decreased from 12 of 16 (75%) to 11 of 16 (69%). In terms of relative erectile function, 10 of 12 patients (83%, 95% CI 55e95) with erection sufficient for penetration remained so. The use of phosphodiesterase-5 inhibitors remained stable at 2 of 16 men (13%).
There were no serious adverse events. Overall, 14 grade I and 19 grade II adverse events developed. Of these events 10 urinary adverse events were considered possibly to likely related to the operation, including 5 cases (26.3%) of persistent debris, hematuria or dysuria, 4 (21%) of urinary tract infection and 1 urethral stricture (5.2%) requiring dilation using local anesthetic. In terms of cancer control, median PSA significantly decreased from 7.75 to 1.71 ng/ml, corresponding to a 78% decrease (IQR 1.33e4.67, p ¼ 0.001, supplementary table, http://jurology.com/). The 6-month mpMRI showed no new lesion that had not been detected at the outset of the study. One man refused biopsy and the 6-month MRI showed equivocal findings (Likert 3). No residual cancer was found in 11 patients (61.1%) ( fig. 2) . In-field residual disease was found in 7 men (38.9%), including 1 (5.6%) who harbored clinically insignificant disease (1 core of a total of 9 positive with 3 mm Gleason 3 þ 3) , and the remaining 6 (33.3%) harbored clinically significant disease ( fig. 3) . Of the latter cases 1 was clinically significant due to a cancer core length of 7 mm (Gleason 3 þ 3 ¼ 6) but the others harbored Gleason 3 þ 4 ¼ 7 with a median maximum cancer core length of 4 mm (IQR 2.5e5.5). One of these 6 men underwent radical prostatectomy, which showed pT2cN0 Gleason 3 þ 4 ¼ 7 with a significant posttreatment effect and residual tumor volume measuring 0.8 ml. One man underwent focal HIFU while 2 were on the list for focal HIFU and focal cryotherapy, respectively, by study end. The remaining patients with residual disease elected active surveillance. No man died or experienced distant disease. Overall, 6 of the 12 patients (50%, 95% CI 25e75) with good functional status at baseline who completed the study achieved trifecta status.
DISCUSSION
Focal IRE delivered to the index lesion conferred a low rate of genitourinary toxicity with preservation of continence in all men and preservation of potency in around 80%. The treatment seemed to have minimal impact on health status and no serious adverse events developed. Ablation results were less satisfactory with a third of patients harboring clinically significant disease following treatment.
Our study has some limitations. 1) The sample size was small and some estimates have wide CIs. While sample size was adherent to the IDEAL recommendations for assessing novel technologies in stage IIa studies, only 16 of 20 patients (80%) had data available at 12 months to measure the primary outcome. Indeed, 1 man was not treated, 1 preferred to be followed elsewhere and 2 received further local treatment. 2) We selected only men with visible anterior disease. Therefore, the results of this study might not be applicable to all men with local disease who undergo focal IRE. 3) This study should be regarded as an evaluation of the novel technology, IRE, rather than as an evaluation of focal therapy. This is in light of the short followup, the small sample size and the novelty of the procedure.
Our early prospective development study confirmed the low toxicity of focal IRE. There were no serious adverse events and genitourinary functional preservation was high. This might reflect the intrinsic characteristics of IRE, which leads to ablation with little damage to surrounding structures, or it might be related to the anterior location of the ablated area, which was well away from the neurovascular bundles and the external urinary sphincter. Further, focal IRE seems to lead to a significant improvement in voiding and storage urinary symptoms. This is also likely to be related to the anterior location of the tumors, leading to benign prostatic hyperplastic tissue undergoing the treatment effect as well.
Disease control based on post-IRE biopsies was somewhat lower than reported for thermal ablation Figure 2 . Case study with no residual tumor in treated area methods. There might be a few explanations for this. 1) In a post hoc analysis we compared patient and tumor characteristics to explore predictors of failure (table 2) . Tumor volume and aggressiveness did not seem different in the 2 groups. The only statistically significant predictor was tumor laterality, that is whether it was unilateral or bilateral (p ¼ 0.049). In other words, if the tumor crossed the midline anteriorly, it was more likely to be incompletely treated. It remains to be determined whether this was because the presence of the transurethral catheter provoked variation in the electric field, or because of the location of the needles, which were positioned at least 5 mm from the urethra.
2) The margins of the treatment areas were tight. Indeed, we positioned the needles just at the margins of the lesion. Recent evidence showed that the oncologic margin to achieve complete ablation should be up to 9 mm in larger lesions, a threshold that we did not respect. 18 3) We currently lack reliable measures of intraoperative monitoring during ablation. The delivery of energy is actually visible on TRUS. However, to our knowledge validated quantitative or qualitative measures to interpret these images are not currently available.
4) The treatment protocol that we used was derived from liver ablation and might be inappropriate for prostatic tissue ablation. Another group using the same treatment protocol as ours reported a similar positive biopsy rate after focal IRE. 12 Other investigators achieved better histological outcomes. In 1 study complete ablation was achieved within the targeted area using a modified protocol of 90 pulses with a pulse length of 90 microseconds. 10 In another study, residual cancer was detected in 16% of men, although the authors did not report the pulse length used. 13 
CONCLUSIONS
Focal IRE confers low risk of genitourinary toxicity. The rate of residual disease in the treatment area might be the result of narrow margins or incomplete ablation using the protocol delivered. Further studies are needed to determine optimal selection criteria and treatment delivery.
